Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation

详细信息    查看全文

• 作者：Edward J. Hennessy ; Claudio Chuaqui ; Susan Ashton ; Nicola Colclough ; Darren A. E. Cross ; Judit É. Debreczeni ; Cath Eberlein ; Lakshmaiah Gingipalli ; Teresa C. M. Klinowska ; Jonathan P. Orme ; Li Sha ; Xiaoyun Wu
• 刊名：ACS Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：May 12, 2016
• 年：2016
• 卷：7
• 期：5
• 页码：514-519
• 全文大小：391K
• 年卷期：0
• ISSN：1948-5875

文摘

A novel series of covalent inhibitors of EGFR (epidermal growth factor receptor) kinase was discovered through a combination of subset screening and structure-based design. These compounds preferentially inhibit mutant forms of EGFR (activating mutant and T790M mutant) over wild-type EGFR in cellular assays measuring EGFR autophosphorylation and proliferation, suggesting an improved therapeutic index in non-small cell lung cancer patients would be achievable relative to established EGFR inhibitors. We describe our design approaches, resulting in the identification of the lead compound 5, and our efforts to develop an understanding of the structure–activity relationships within this series. In addition, strategies to overcome challenges around metabolic stability and aqueous solubility are discussed. Despite limitations in its physical properties, 5 is orally bioavailable in mice and demonstrates pronounced antitumor activity in in vivo models of mutant EGFR-driven cancers.